Print

AVEG 011

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) February 04, 1993
UBI HIV-1 Peptide Immunogen, Multivalent Env eight branched peptides derived from V3 loop of gp120
UBI HIV-1 Peptide Immunogen, Multivalent Protein
USA 40
NCT00000775
https://clinicaltrials.gov/show/NCT00000775